- Prophylactic
- Topiramate
- Botulinum toxin
- Abortive
- Ergot Alkaloids
- Triptans
Migraine Drugs Market size was valued at USD 5.5 billion in 2023, growing at a significant CAGR of 9.5% from 2024-2030. Migraine Drugs Market is a primary headache disorder characterized by moderate to a severe headache. Typically migraine headaches affect half of the head and are generally pulsatile. A migraine may last in the range of two hours to 72 hours. Other symptoms may include nausea, vomiting, and sensitivity to light, smell, and sound. Migraines may be preceded by an aura of sensory disturbances followed by severing an often onside headache. There are two types of migraine drugs are present in the market. Prophylactic drugs are used for the prevention of precedence of migraine. Whereas, no particular migraine therapy drugs are available. The migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, the rise in R&D activities by the market players to develop new drugs and the expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in the population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs and other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period. The global migraine drugs market is expected to grow at a significant rate owing to the prevalence of migraine worldwide. The market is witnessing acquisitions and mergers of the market players.
Key Developments:
- In March 2017, Eli Lilly and Company acquired migraine drugs company, CoLucid Pharmaceuticals for about US $960Mn.
- In June 2017, Grenenthal agreed to acquire global rights for AstraZeneca's migraine drug Zomig, outside Japanese market. Furthermore, the market has many drugs which are under development for the treatment of a migraine.
Global Migraine Drugs Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Migraine Drugs Market Dynamics
Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period.
North-America Got Significant Share
Migraine Drugs Market Regional Analysis
Geographically migraine drugs market is divided into five key regions, i.e. Europe, North America, Latin America, Asia- Pacific, and The Middle East & Africa. North America migraine drugs market is anticipated to grow at significant rates owing to the factors such as rise in the occurrence of migraine, greater healthcare expenditure, and recent product launches. Asia Pacific market is expected to have notable market growth over the forecast period owing to the growth in a number of people suffering from the migraine and growing awareness related to early diagnosis and treatment. China and India expected to have lucrative growth opportunities owing to the lifestyle changes and high prevalence rates of migraine in the countries
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Migraine Drugs Market Segmentation
By Drug Type
By Route of Administration
- Injectables
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Frequently Asked Questions
The migraine drugs market size was valued at USD 5.5 billion in 2023
The Migraine Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Migraine Drugs Market key players AstraZeneca Plc. (U.K.), Allergan Plc. (U.S.), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (U.K), Eli Lilly & Co. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Valeant Pharmaceutical International, Inc. (Canada), Janssen Pharmaceutical Company (Johnson & Johnson) (U.S.), Endo International plc. (U.S.), Zosano Pharma Inc. (U.S.), Alder Biopharmaceuticals (U.S.)
| 1. Executive Summary |
| 2. Global Migraine Drugs Market Introduction |
| 2.1.Global Migraine Drugs Market - Taxonomy |
| 2.2.Global Migraine Drugs Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Route of Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Migraine Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Migraine Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Migraine Drugs Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Prophylactic |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Abortive |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Migraine Drugs Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Injectables |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oral |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Migraine Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Migraine Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Migraine Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Prophylactic |
| 9.1.2.Abortive |
| 9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Injectables |
| 9.2.2.Oral |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Migraine Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Prophylactic |
| 10.1.2.Abortive |
| 10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Injectables |
| 10.2.2.Oral |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Migraine Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Prophylactic |
| 11.1.2.Abortive |
| 11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Injectables |
| 11.2.2.Oral |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Migraine Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Prophylactic |
| 12.1.2.Abortive |
| 12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Injectables |
| 12.2.2.Oral |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Migraine Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Prophylactic |
| 13.1.2.Abortive |
| 13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Injectables |
| 13.2.2.Oral |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AstraZeneca Plc. (U.K) |
| 14.2.2.Allergan Plc. (U.S) |
| 14.2.3.Pfizer, Inc. (U.S) |
| 14.2.4.Teva Pharmaceutical Industries Ltd. (Israel) |
| 14.2.5.GlaxoSmithKline plc (U.K) |
| 14.2.6.Eli Lilly & Co. (U.S) |
| 14.2.7.Novartis AG (Switzerland) |
| 14.2.8.Merck & Co., Inc. (U.S) |
| 14.2.9.Valeant Pharmaceutical International, Inc. (Canada) |
| 14.2.10.Janssen Pharmaceutical Company (Johnson & Johnson) (U.S) |
| 14.2.11.Endo International plc. (U.S) |
| 14.2.12.Zosano Pharma Inc. (U.S) |
| 14.2.13.Alder Biopharmaceuticals (U.S) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- AstraZeneca Plc. (U.K)
- Allergan Plc. (U.S)
- Pfizer, Inc. (U.S)
- Teva Pharmaceutical Industries Ltd. (Israel)
- GlaxoSmithKline plc (U.K)
- Eli Lilly & Co. (U.S)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S)
- Valeant Pharmaceutical International, Inc. (Canada)
- Janssen Pharmaceutical Company (Johnson & Johnson) (U.S)
- Endo International plc. (U.S)
- Zosano Pharma Inc. (U.S)
- Alder Biopharmaceuticals (U.S)